X4 Pharmaceuticals (XFOR) Net Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) reported Net Margin of 931.66% for Q4 2025, up 184526.0% on a YoY basis from N/an in Q4 2024, and up 44.85% quarter-over-quarter from 1689.24% in Q3 2025.
X4 Pharmaceuticals (XFOR) Net Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Net Margin for 4 years, with the latest figure at 931.66% in Q4 2025.
- For the quarter ending Q4 2025, Net Margin rose 184526.0% year-over-year to 931.66%; the trailing twelve-month figure through Dec 2025 stood at 225.55% (up 123905.0% YoY), and the FY2025 full-year result was 225.55%, up 124101.0% from the prior year.
- Net Margin for Q4 2025 stood at 931.66%, up from 1689.24% in the prior quarter.
- The five-year high for Net Margin was 16133.75% in Q2 2024, with the low at 6552.86% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | -931.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -931.66% |
| Sep 30, 2025 | -1,689.24% |
| Jun 30, 2025 | -1,304.66% |
| Mar 31, 2025 | 0.98% |
| Dec 31, 2024 | -2,776.92% |
| Sep 30, 2024 | -6,552.86% |
| Jun 30, 2024 | 16,133.75% |
| Mar 31, 2020 | -371.27% |
| Dec 31, 2018 | -343.94% |